Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B

Blood

Volumn 120, Issue 18, 2012, Pages 3764-3773

  Rao, Shuyun ^a   Lee, Sang Yun ^a   Gutierrez, Alejandro ^b   Perrigoue, Jacqueline ^a   Thapa, Roshan J ^a   Tu, Zhigang ^a   Jeffers, John R ^c   Rhodes, Michele ^a   Anderson, Stephen ^d   Oravecz, Tamas ^d   Hunger, Stephen P ^e   Timakhov, Roman A ^a   Zhang, Rugang ^a   Balachandran, Siddharth ^a   Zambetti, Gerard P ^c   Testa, Joseph R ^a   Look, A Thomas ^b   Wiest, David L ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d LEXICON PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; LIN28B PROTEIN; RIBOSOME L22 PROTEIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENE INACTIVATION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; THYMUS LYMPHOMA;

EID: 84868526281     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-415349     Document Type: Article

References (50)

1. Neumann F, Krawinkel U. Constitutive expression of human ribosomal protein L7 arrests the cell cycle in G1 and induces apoptosis in Jurkat T-lymphoma cells. Exp Cell Res. 1997;230(2):252-261. (Pubitemid 27190645)
2. Mazumder B, Sampath P, Seshadri V, Maitra RK, DiCorleto PE, Fox PL. Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control. Cell. 2003;115(2):187-198. (Pubitemid 37329582)
3. Ball S. Diamond Blackfan anemia. Hematology Am Soc Hematol Educ Program. 2011;2011:487-491.
4. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
5. Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115(16):3196-3205.
6. Amsterdam A, Hopkins N. Retroviral-mediated insertional mutagenesis in zebrafish. Methods Cell Biol. 2004;77:3-20.
7. Matsson H, Davey EJ, Draptchinskaia N, et al. Targeted disruption of the ribosomal protein S19 gene is lethal prior to implantation. Mol Cell Biol. 2004;24(9):4032-4037. (Pubitemid 38496179)
8. Oliver ER, Saunders TL, Tarle SA, Glaser T. Ribosomal protein L24 defect in belly spot and tail (Bst), a mouse Minute. Development. 2004;131(16):3907- 3920. (Pubitemid 39232151)
9. Anderson SJ, Lauritsen JP, Hartman MG, et al. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. Immunity. 2007;26(6):759-772. (Pubitemid 46907667)
10. Amsterdam A, Sadler KC, Lai K, et al. Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol. 2004;2(5):E139.
11. Gutierrez A, Sanda T, Grebliunaite R, et al. High frequency of PTEN, PI3K and AKT abnormalities in T cell acute lymphoblastic leukemia. Blood. 2009;114(3):647-650.
12. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13(20):2658-2669. (Pubitemid 29508553)
13. Stadanlick JE, Zhang Z, Lee SY, et al. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. J Immunol. 2011;187(2):664-675.
14. Kennedy AL, Morton JP, Manoharan I, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 2011;42(1):36-49.
15. Viswanathan SR, Powers JT, Einhorn W, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843-848.
16. Haks MC, Lefebvre JM, Lauritsen JP, et al. Attenuation of gammadeltaTCR signaling efficiently diverts thymocytes to the alphabeta lineage. Immunity. 2005;22(5):595-606. (Pubitemid 40719195)
17. Thapa RJ, Basagoudanavar SH, Nogusa S, et al. NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol. 2011;31(14):2934-2946.
18. Choi YL, Tsukasaki K, O'Neill MC, et al. A genomic analysis of adult T-cell leukemia. Oncogene. 2007;26(8):1245-1255.
19. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14(5):518-527. (Pubitemid 351655218)
20. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795. (Pubitemid 33115977)
21. Timakhov RA, Tan Y, Rao M, et al. Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice. Genes Chromosomes Cancer. 2009;48(9):786-794.
22. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210. (Pubitemid 47530629)
23. Bhat KP, Itahana K, Jin A, Zhang Y. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. EMBO J. 2004;23(12):2402-2412. (Pubitemid 38954847)
24. Dai MS, Lu H. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem. 2004;279(43):44475-44482. (Pubitemid 39430853)
25. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol. 2004;24(17):7654-7668. (Pubitemid 39121491)
26. Zhu Y, Poyurovsky MV, Li Y, et al. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Mol Cell. 2009;35(3):316-326.
27. Zindy F, Eischen CM, Randle DH, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12(15):2424-2433. (Pubitemid 28371361)
28. Jeffers JR, Parganas E, Lee Y, et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell. 2003;4(4):321-328. (Pubitemid 37329796)
29. Guo Y, Chen Y, Ito H, et al. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene. 2006;384:51-61. (Pubitemid 44755336)
30. King CE, Wang L, Winograd R, et al. LIN28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene. 2011;30(40):4185-4193.
31. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008;320(5872):97-100. (Pubitemid 351490762)
32. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 Micro-RNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693-706.
33. Espinosa L, Cathelin S, D'Altri T, et al. The Notch/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell. 2010;18(3):268-281.
34. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271. (Pubitemid 39336870)
35. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011;12(8):695-708.
36. MacInnes AW, Amsterdam A, Whittaker CA, Hopkins N, Lees JA. Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A. 2008;105(30):10408-10413.
37. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004;83(12):769-774.
38. Barna M, Pusic A, Zollo O, et al. Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature. 2008;456(7224):971-975.
39. Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mROR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010;17(3):249-261.
40. Kondrashov N, Pusic A, Stumpf CR, et al. Ribosome-mediated specificity in Hox mRNA translation and vertebrate tissue patterning. Cell. 2011;145(3):383-397.
41. Wang Y, Mah N, Prigione A, Wolfrum K, Andrade-Navarro MA, Adjaye J. A transcriptional roadmap to the induction of pluripotency in somatic cells. Stem Cell Rev. 2010;6(2):282-296.
42. Rybak A, Fuchs H, Smirnova L, et al. A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol. 2008;10(8):987-993.
43. Yuan J, Nguyen CK, Liu X, Kanellopoulou C, Muljo SA. Lin28b reprograms adult bone marrow hematopoietic progenitors to mediate fetal-like lymphopoiesis. Science. 2012;335(6073):1195-1200.
44. Beachy SH, Onozawa M, Chung YJ, et al. Enforced expression of Lin28b leads to impaired T-cell development, release of inflammatory cytokines and peripheral T-cell lymphoma. Blood. 2012;120(5):1048-1059.
45. Balzer E, Heine C, Jiang Q, Lee VM, Moss EG. LIN28 alters cell fate succession and acts independently of the let-7 microRNA during neurogliogenesis in vitro. Development. 2010;137(6):891-900.
46. Wan F, Anderson DE, Barnitz RA, et al. Ribosomal protein S3: a KH domain subunit in NFkappaB complexes that mediates selective gene regulation. Cell. 2007;131(5):927-939. (Pubitemid 350138085)
47. Ben-Shem A, Garreau de Loubresse N, et al. The structure of the eukaryotic ribosome at 3.0 A resolution. Science. 2011;334(6062):1524-1529.
48. Fine BM, Stanulla M, Schrappe M, et al. Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. Blood. 2004;103(3):1043-1049. (Pubitemid 38129570)
49. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. BioFactors. 2007;29(1):19-35. (Pubitemid 46985299)
50. Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-kappaB activity. Leuk Lymphoma. 2011;52(12):2393-2395.